Search

Displaying results 1061 - 1070 of 10000 in total
  1. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H … It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  2. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  3. Drug

    Nazartinib

    go.drugbank.com/drugs/DB16250
    Investigational

    Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating

  4. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze
  5. Drug

    Streptococcus pneumoniae type 23f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10340
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze
  6. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    in the small intestine. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias

    Mixtures: EnLyte Extra-LN
  7. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  8. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608]. … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].

  9. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.

  10. Drug

    Pegilodecakin

    go.drugbank.com/drugs/DB15162
    Investigational

    Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small

    Synonyms: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED